Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMICUS THERAPEUTICS, INC.FOLD · Entity 51196 | Director | June 10, 2021 | June 14, 2021 |
| Organon & Co.OGN · Entity 4115 | Director | June 12, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMICUS THERAPEUTICS, INC.
Report date June 10, 2021 · Filed June 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,115 |
Reported balance
After 2021-06-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-06-10 · Grant · Acquired 10,115 · Balance 31,115 F1: Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.71 · Expires 2031-06-10 | Direct | 36,111 |
Reported balance
After 2021-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-06-10 · Grant · Acquired 36,111 · Balance 36,111 F2: One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock.
F2: One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant.
Organon & Co.
Report date June 12, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom StockSEC Table II · derivative / convertible security | Direct | 81,141.129 |
Reported balance
After 2026-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-12 · Grant · Acquired 17,857.143 · Balance 81,141.129 F1: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3: Holdings include phantom stock acquired in dividend reinvestment transactions on September 11, 2025, December 11, 2025, March 12, 2026 and June 11, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1.
F2: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.
F3: Holdings include phantom stock acquired in dividend reinvestment transactions on September 11, 2025, December 11, 2025, March 12, 2026 and June 11, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2026 Filed Jun 15, 2026 20:32 UTC | Organon & Co. OGN · Entity 4115 | GrantPhantom Stock · Derivative | 17,857.143 | $13.44 | $240,000.00 |
DisclosureSEC source: 0001628280-26-043218 · wk-form4_1781555540.xml · derivative · entry 1 ESSNER ROBERT · CIK 0001187297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,141.129 Underlying: Common Stock · 17,857.143 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on September 11, 2025, December 11, 2025, March 12, 2026 and June 11, 2026. Read SEC document |
| June 13, 2025 Filed Jun 16, 2025 21:19 UTC | Organon & Co. OGN · Entity 4115 | GrantPhantom Stock · Derivative | 23,904.382 | $10.04 | $240,000.00 |
DisclosureSEC source: 0001821825-25-000043 · wk-form4_1750108745.xml · derivative · entry 1 ESSNER ROBERT · CIK 0001187297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,702.652 Underlying: Common Stock · 23,904.382 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock units acquired in dividend reinvestment transactions on June 13, 2024, September 12, 2024, December 12, 2024, March 13, 2025 and June 12, 2025. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 19:16 UTC | Organon & Co. OGN · Entity 4115 | GrantPhantom Stock · Derivative | 9,638.554 | $20.75 | $200,000.00 |
DisclosureSEC source: 0001821825-24-000074 · wk-form4_1718133408.xml · derivative · entry 1 ESSNER ROBERT · CIK 0001187297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,454.813 Underlying: Common Stock · 9,638.554 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on June 15, 2023, September 14, 2023, December 14, 2023 and March 14, 2024. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 20:48 UTC | Organon & Co. OGN · Entity 4115 | GrantPhantom Stock · Derivative | 10,086 | $19.83 | $200,005.38 |
DisclosureSEC source: 0001209191-23-036761 · doc4.xml · derivative · entry 1 ESSNER ROBERT · CIK 0001187297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,285 Underlying: Common Stock · 10,086 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on June 16, 2022, September 15, 2022, December 15, 2022 and March 16, 2023. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 23:33 UTC | Organon & Co. OGN · Entity 4115 | GrantPhantom Stock · Derivative | 5,640 | $35.46 | $199,994.40 |
DisclosureSEC source: 0001104659-22-071135 · tm2218336-3_4seq1.xml · derivative · entry 1 ESSNER ROBERT · CIK 0001187297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,638 Underlying: Common Stock · 5,640 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on September 13, 2021, December 16, 2021 and March 17, 2022. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 23:14 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantStock Options (right to buy) · Derivative | 36,111 | $0.00 Strike: $10.71 | $0.00 |
DisclosureSEC source: 0001209191-21-040399 · doc4.xml · derivative · entry 2 ESSNER ROBERT · CIK 0001187297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,111 Underlying: Common Stock · 36,111 shares Expires 2031-06-10 F2 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 23:14 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 10,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040399 · doc4.xml · nonDerivative · entry 1 ESSNER ROBERT · CIK 0001187297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,115 F1 · security: Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock. Read SEC document |
| June 04, 2021 Filed Jun 9, 2021 00:36 UTC | Organon & Co. OGN · Entity 4115 | GrantPhantom Stock · Derivative | 8,772 | $36.05 | $316,230.60 |
DisclosureSEC source: 0000899243-21-022677 · doc4.xml · derivative · entry 1 ESSNER ROBERT · CIK 0001187297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,772 Underlying: Common Stock · 8,772 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the separation of Organon & Co. ("Organon") from Merck & Co., Inc. (the "Separation"), which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,223 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases. F2 · derivative.expiration_date: Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the separation of Organon & Co. ("Organon") from Merck & Co., Inc. (the "Separation"), which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,223 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 21:03 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantStock Options (right to buy) · Derivative | 18,574 | $0.00 Strike: $12.81 | $0.00 |
DisclosureSEC source: 0001209191-20-035014 · doc4.xml · derivative · entry 2 ESSNER ROBERT · CIK 0001187297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,574 Underlying: Common Stock · 18,574 shares Expires 2030-06-04 F2 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 21:03 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 5,855 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-035014 · doc4.xml · nonDerivative · entry 1 ESSNER ROBERT · CIK 0001187297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 F1 · security: Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock. Read SEC document |
| June 27, 2019 Filed Jul 1, 2019 20:56 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantStock Options (right to buy) · Derivative | 19,473 | $0.00 Strike: $12.00 | $0.00 |
DisclosureSEC source: 0001209191-19-039760 · doc4.xml · derivative · entry 2 ESSNER ROBERT · CIK 0001187297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,473 Underlying: Common Stock · 19,473 shares Expires 2029-06-27 F2 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the date of the annual meeting of the stockholders of the issuer to be held in 2020. Read SEC document |
| June 27, 2019 Filed Jul 1, 2019 20:56 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-039760 · doc4.xml · nonDerivative · entry 1 ESSNER ROBERT · CIK 0001187297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,145 F1 · shares: The Restricted Stock Units will vest one year after date of grant and vested shares will be payable in common stock. One (1) Restricted Stock Unit is the equivalent of one (1) share of Amicus Therapeutics, Inc. common stock. Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 20:43 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantStock Options (right to buy) · Derivative | 8,912 | $0.00 Strike: $16.23 | $0.00 |
DisclosureSEC source: 0001209191-18-036996 · doc4.xml · derivative · entry 2 ESSNER ROBERT · CIK 0001187297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,912 Underlying: Common Stock · 8,912 shares Expires 2028-06-07 F2 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the date of the annual meeting of the stockholders of the issuer to be held in 2019. Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 20:43 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 3,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-036996 · doc4.xml · nonDerivative · entry 1 ESSNER ROBERT · CIK 0001187297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,895 F1 · shares: The Restricted Stock Units will vest one year after date of grant and vested shares will be payable in common stock. One (1) Restricted Stock Unit is the equivalent of one (1) share of Amicus Therapeutics common stock. Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 20:05 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantStock Options (right to buy) · Derivative | 16,236 | $0.00 Strike: $8.60 | $0.00 |
DisclosureSEC source: 0001209191-17-040100 · doc4.xml · derivative · entry 2 ESSNER ROBERT · CIK 0001187297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,236 Underlying: Common Stock · 16,236 shares Expires 2027-06-13 F1 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the date of the annual meeting of the stockholders of the issuer to be held in 2018. Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 20:05 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 5,814 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-040100 · doc4.xml · nonDerivative · entry 1 ESSNER ROBERT · CIK 0001187297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,814 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.